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Pharmacological and psychotherapeutic interventions for 
management of obsessive-compulsive disorder in adults: 
a systematic review and network meta-analysis
Petros Skapinakis, Deborah M Caldwell, William Hollingworth, Peter Bryden, Naomi A Fineberg, Paul Salkovskis, Nicky J Welton, Helen Baxter, 
David Kessler, Rachel Churchill, Glyn Lewis
Summary
Background Several interventions are available for management of obsessive-compulsive disorder in adults, but few 
studies have compared their relative eﬃ  cacy in a single analysis. We aimed to simultaneously compare all available 
treatments using both direct and indirect data.
Methods In this systematic review and network meta-analysis, we searched the two controlled trials registers 
maintained by the Cochrane Collaboration Common Mental Disorders group for trials published up to Feb 16, 2016. 
We selected randomised controlled trials in which an active psychotherapeutic or pharmacological intervention had 
been used in adults with obsessive-compulsive disorder. We allowed all comorbidities except for schizophrenia or 
bipolar disorder. We excluded studies that focused exclusively on treatment-resistant patient populations deﬁ ned 
within the same study. We extracted data from published reports. The primary outcome was symptom severity as 
measured by the Yale-Brown Obsessive Compulsive Scale. We report mean diﬀ erences with 95% credible intervals 
compared with placebo. This study is registered with PROSPERO, number CRD42012002441.
Findings We identiﬁ ed 1480 articles in our search and included 53 articles (54 trials; 6652 participants) in the network 
meta-analysis. Behavioural therapy (mean diﬀ erence –14·48 [95% credible interval –18·61 to –10·23]; 11 trials and 
287 patients), cognitive therapy (–13·36 [–18·40 to –8·21]; six trials and 172 patients), behavioural therapy and 
clomipramine (–12·97 [–19·18 to –6·74]; one trial and 31 patients), cognitive behavioural therapy and ﬂ uvoxamine 
(–7·50 [–13·89 to –1·17]; one trial and six patients), cognitive behavioural therapy (–5·37 [–9·10 to –1·63]; nine trials 
and 231 patients), clomipramine (–4·72 [–6·85 to –2·60]; 13 trials and 831 patients), and all SSRIs (class eﬀ ect –3·49 
[95% credible interval –5·12 to –1·81]; 37 trials and 3158 patients) had greater eﬀ ects than did drug placebo. 
Clomipramine was not better than were SSRIs (–1·23 [–3·41 to 0·94]). Psychotherapeutic interventions had a greater 
eﬀ ect than did medications, but a serious limitation was that most psychotherapeutic trials included patients who 
were taking stable doses of antidepressants (12 [80%] of the 15 psychotherapy trials explicitly allowed antidepressants).
Interpretation A range of interventions is eﬀ ective in the management of obsessive-compulsive disorder, but 
considerable uncertainty and limitations exist regarding their relative eﬃ  cacy. Taking all the evidence into account, 
the combination of psychotherapeutic and psychopharmacological interventions is likely to be more eﬀ ective than are 
psychotherapeutic interventions alone, at least in severe obsessive-compulsive disorder.
Funding National Institute for Health Research.
Copyright © Skapinakis et al. Open Access article published under the terms of CC BY.
Introduction
Obsessive compulsive disorder is considered the fourth 
most common mental disorder in high-income countries 
and ranks as the tenth leading cause of disability 
worldwide.1,2 It is associated with increased mortality3 and 
can have a substantial impact on quality of life for both 
patients and family members or carers.2 Clomipramine 
and the SSRIs are currently recommended for pharma-
cological management of the disease.4 Psychotherapies 
and especially behavioural or cognitive behavioural inter-
ventions have been developed5,6 and are also 
recommended.7
Previous systematic reviews and meta-analyses have 
generally compared the eﬃ  cacy of pharmacological 
interventions with placebo, not with each other.8–10 
Psychotherapeutic interventions have typically been 
compared with a waiting list or other inactive therapy.7,11 
Only a few studies have directly compared psycho-
therapeutic with pharmacological interventions or comb-
inations of them, and their results are inconclusive.7 In 
the absence of available head-to-head comparisons, 
indirect evidence can be used to enhance the existing 
evidence base. Indirect comparisons between diﬀ erent 
medications have been done in the past, but statistical 
methods appropriate for such comparisons were poorly 
developed at that time.10 Network meta-analysis is a 
method of synthesising information from a network of 
trials addressing the same question, but involving 
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diﬀ erent interventions. It aims to combine direct and 
indirect evidence into a single eﬀ ect size and rank all 
available treatments in terms of eﬃ  cacy, providing 
estimates for interventions even if they have not 
been directly compared. This approach has been 
applied success fully to schizophrenia, bipolar disorder, 
depression, and certain anxiety disorders (social phobia 
and generalised anxiety disorder), but not obsessive-
compulsive disorder. We therefore did a systematic review 
and network meta-analysis with the aim to simultaneously 
compare all available treatments using both direct and 
indirect data.12 A more detailed report than this one will 
be published, and data collected for children and 
adolescents will also be separately published.
Methods
Search strategy and selection criteria
In this systematic review and network meta-analysis, we 
searched the two controlled trials registers maintained 
by the Cochrane Collaboration Common Mental 
Disorders group for trials published up to Feb 16, 2016, 
by experienced staﬀ  of the Cochrane Common Mental 
Disorders group using their standard methodology. 
Reports of trials for inclusion in the Group’s registers 
are collated from routine (weekly), generic searches of 
MEDLINE, Embase, and PsycINFO; quarterly searches 
of the Cochrane Central Register of Controlled Trials; 
and review-speciﬁ c searches of additional databases. 
We searched the registers using the generic term 
“condition = obsess* OR compulsi*”, with no language 
restrictions. We included studies in the review if they 
were randomised controlled trials of adult patients 
with a diagnosis of obsessive-compulsive disorder. We 
allowed all comorbidities except for schizophrenia or 
bipolar disorder. We excluded studies that focused 
exclusively on treatment-resistant patient populations 
deﬁ ned within the same study.
Eligible experimental interventions were all anti-
depressants7 and psychotherapeutic interventions7 recom-
mended by current guidelines—ie, behavioural therapy, 
including exposure and response prevention but not 
explicit cognitive techniques (such as cognitive 
restructuring); cognitive therapy, including cognitive 
restructuring but not explicit behavioural techniques; and 
cognitive behavioural therapy (CBT). In psycho therapy 
trials that used both an individual and group format, we 
extracted data only for groups with the individual format. 
Eligible control interventions were drug placebo, 
psychological placebo (any credible psychological inter-
vention that includes only non-speciﬁ c components of 
therapy, such as general stress manage ment or relaxation), 
and any other non-speciﬁ c psycho therapeutic relationship. 
Inclusion and exclusion criteria were independently 
assessed by two reviewers (HB and PSk) and validated by 
one reviewer (PSk). For studies that were excluded, we 
noted the main reason for exclusion. 
Research in context
Evidence before this study
During the protocol stage of our project (May 1 to June 30, 2013), 
we did a scoping search of the literature. We used the two 
specialised registers of controlled trials maintained and 
administered by the Cochrane Collaboration Common Mental 
Disorders Group. We searched the registers using the generic 
term “condition = obsess* OR compulsi*”, with no language or 
date restrictions. We found that the latest comprehensive 
review had been published in 2006 and specifi c meta-analyses 
had been published in 2008. Since then, several new trials have 
been done. Previous systematic reviews and meta-analyses 
have generally focused on the comparison between 
antidepressant medications and placebo or psychotherapeutic 
interventions and a waiting list. Few studies have directly 
compared the relative effi  cacy of serotonergic antidepressants 
versus each other, behavioural-type psychotherapies versus 
each other, or medications versus psychotherapies. Clinicians 
are often interested in pragmatic comparisons (Are all SSRIs 
equally eff ective? Is clomipramine more eff ective than are 
SSRIs? Is cognitive behavioural psychotherapy more eff ective 
than are medications?), but these questions have been 
examined in few studies in the past using statistical methods 
that have not always taken into account the complexity of such 
comparisons. We therefore did a network meta-analysis with 
the aim to simultaneously compare in a single analysis and 
rank in terms of effi  cacy all available interventions for 
management of obsessive-compulsive disorder in adults.
Added value of this study
We found small diff erences in effi  cacy between medications, 
and the hypothesis of clomipramine being better than SSRIs 
was not confi rmed. Although certain psychotherapies were 
associated with larger eff ects than were medications, we 
underline an important limitation that, in most 
psychotherapeutic trials, patients who were taking stable 
doses of antidepressants were not excluded and therefore 
these therapies cannot be considered as pure monotherapies.
Implications of all the available evidence
Taking all evidence into account, the combination of 
psychotherapies with medications is possibly the most 
eff ective intervention and clinicians should consider this 
option more often than at present for patients with severe 
obsessive-compulsive disorder. Psychotherapy is eff ective in 
symptomatic patients taking antidepressant medications, and 
its eff ect as monotherapy is not known. Future research 
should try to diff erentiate more clearly the eff ect of 
medications versus psychotherapy and monotherapy versus 
combined therapy, avoiding the limitations that we have 
underlined in this study. 
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Data analysis
Data extraction was done independently by two reviewers 
(HB and PSk) and validated by one reviewer (PSk). 
We used standardised data extraction Word forms and 
structured Excel spreadsheets to extract data from 
published reports. In cases of duplicate data, we selected 
the manuscript with the largest sample. We also 
considered preliminary congress abstracts duplicate and 
did not select them if a full article had been published 
after the congress. We extracted data for inclusion 
and exclusion criteria (study design, experimental 
intervention, control intervention, age range, primary 
diagnosis, comorbid diagnoses, and use of diagnostic 
criteria), general details of the study (country, treatment 
setting, and length of follow-up), details of continuous 
outcome assessment (number of patients eligible for 
randomisation, randomised, dropped out, and remaining 
at the end of study, and baseline, end of treatment, and 
change from baseline Yale-Brown Obsessive Compulsive 
Scale [YBOCS] scores, with SDs), and details of the risk 
of bias assessment (intention-to-treat analysis, use of 
methods for handling missing data, and dropouts).
For the quantitative synthesis, the primary outcome 
measure was continuous and it was symptom severity as 
measured by YBOCS.13 Our preferred measure was 
mean change from baseline score. For studies in which 
this measure was not reported, we used mean YBOCS 
scores at the end of study after checking that YBOCS at 
baseline was balanced across groups. We report mean 
diﬀ erences with 95% credible intervals compared with 
placebo. We assessed risk of bias using the criteria 
suggested by the Cochrane Collaboration Handbook.14 
We included studies with a high risk of bias in the main 
analysis but did sensitivity analyses to examine the eﬀ ect 
of excluding them.
We did pairwise and network meta-analyses for 
eﬃ  cacy. We excluded studies that did not use YBOCS. 
This post-hoc decision was made for two reasons: 
YBOCS is the only available clinician-rated scale that has 
been extensively validated in controlled trials worldwide13 
and use of a single scale allowed us to use the mean 
diﬀ erence instead of the standardised mean diﬀ erence, 
avoiding the metho dological and interpretational diﬃ  -
culties associated with use of standardised mean 
diﬀ erence.14 Where possible, we derived missing SDs 
from reported statistics following guidance in the 
Cochrane Collaboration Handbook.14 Where possible, we 
analysed the intention-to-treat population; otherwise, we 
used reported results for participants who completed 
the study. 
We did all analyses in a Bayesian framework using 
OpenBUGS version 3.2.3. We used the random-eﬀ ect 
models described by Dias and colleagues,15 modiﬁ ed to 
incorporate an additional class hierarchy,16 such that all 
SSRIs were assumed to be similar, with a common 
class mean eﬀ ect and between-SSRI variability about 
this class mean. We used ﬂ at priors for all parameters. 
We assessed heterogeneity by examining the posterior 
median of the between-study heterogeneity parameter 
from the random-eﬀ ects model. To assess variability 
within studies, we used what was reported by trial 
authors. For continuous measures SDs were reported 
and for ratio measures typically SEs. However, where 
these statistics were not reported, we used methods 
recommended by the Cochrane Collaboration Hand-
book14 (eg, estimation of SEs from CIs). We measured 
goodness of ﬁ t with the posterior mean of the residual 
deviance. To assess inconsistency between direct and 
indirect evidence, we compared the ﬁ t of a model 
assuming consistency with that of one that relaxes this 
assumption (unrelated mean-eﬀ ects model).17 We also 
compared the results of the pairwise meta-analysis with 
those of the network meta-analysis. All OpenBUGS 
code is available in the appendix.
Preplanned sensitivity analyses excluded studies at high 
risk of bias for the following domains: masking of the 
outcome assessor, incomplete outcome data, and high 
1480 records identified through database searching  
1458 records screened
158 full-text articles assessed for eligibility
63 articles (64 trials) included in qualitative review
53 articles (54 trials) included in eﬃcacy network 
      meta-analysis (quantitative review)
22 duplicate records removed
1300 records excluded
 1275 not relevant
 25 not assessable because of language 
or unobtainable for screening
95 articles excluded
 22 of children or adolescents
 17 duplicate reports
 17 interventions not specified
 10 non-randomised
 9 non-usable data
 8 preliminary congress abstracts
 5 secondary analyses or relapse 
  prevention studies
 4 obsessive-compulsive disorder not 
  main focus
 3 of treatment-refractory patients
10 articles excluded
 9 did not use YBOCS
 1 not connected to network
Figure 1: Study selection
YBOCS=Yale-Brown Obsessive Compulsive Scale. 
For OpenBUGS see http://www.
openbugs.net
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overall attrition or evidence of diﬀ erential attrition 
between groups. We present the results both before 
(ie, the full dataset) and after excluding waiting list 
controlled trials. These trials are non-masked and evidence 
exists that they lead to biased results in favour of the active 
psychotherapeutic interventions.18–20 We did separate 
meta-regressions assuming a common interaction term 
for the following study-level charac teristics: length of trial, 
publication date, industry sponsorship, and inclusion of 
patients with current comorbid depression. This study is 
registered with PROSPERO, number CRD42012002441.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication. 
Results
We identiﬁ ed 1480 articles in our search and assessed 
158 (11%) full-text articles for eligibility (ﬁ gure 1). 
We excluded 95 (60%) articles and included 64 trials 
reported in 63 (40%) articles21–83 in the qualitative 
review. A detailed list of the excluded studies is in the 
appendix. From the 63 articles eligible for inclusion in 
the network meta-analysis, we excluded ten (16%): 
nine (14%)22,32,35,36,54,62,73,77,80 did not use YBOCS and 
one (2%)47 was not connected to the network (details of 
these studies in appendix), leaving 54 trials reported in 
53 (34%) articles21,23–31,33,34,37–46,48–53,55–61,63–72,74–76,78,79,81–83 included 
in the network meta-analysis (quantitative review). 
7302 patients were randomly allocated in the qualitative 
review; however, 7014 (96%) were randomly allocated 
in the network meta-anlysis, with 288 (4%) excluded. 
Only 6652 (91%) contributed to the network 
meta-analysis since some trials did not report outcomes 
for all participants.
The 64 trials included in the qualitative review were 
published over a period of 33 years (1980–2012; table 1; 
detailed charac teristics in appendix). In most psycho-
therapeutic trials, patients were not excluded if they were 
taking a stable dose of antidepressants for at least 3 months 
before inclusion (13 [72%] of all 18 psychotherapeutic trials 
and 12 [80%] of the 15 psychotherapeutic trials included 
in the network meta-analysis explicitly allowed anti-
depressants). In these trials, the proportion of patients on 
antidepressant medication varied, ranging from 13% to 
100% and, in more than two-thirds of studies with the 
information available, was 45% or higher (detailed des-
cription in appendix). Patients were not allowed to make 
dose adjustments during trials, but no speciﬁ c information 
was provided on how this criterion had been monitored by 
authors. Participants had long-standing and severe 
obsessive-compulsive disorder. Demographic and clinical 
characteristics of participants were similar across 
comparisons.
The 54 trials included in the network meta-analysis 
(quantitative review) involved 17 diﬀ erent treatments 
grouped into 12 classes (all six SSRIs were grouped into 
the same class; ﬁ gure 2). Overall, of the 136 unique 
pairwise comparisons that could be made between the 
17 treatment conditions, only 37 (27%) were studied head 
to head in the included studies. A detailed table of the data 
used in the analysis is in the appendix. Six (11%) trials used 
a waiting list control group: ﬁ ve (9%) CBT studies23,31,40,50,71 
including 157 patients, 80 (51%) of whom had been 
randomly allocated to CBT, and one (2%) behavioural 
All trials (n=64) Trials eligible for 
network 
meta-analysis (n=54)
Eligible patients 7302 7014
Sample size 66 (31–159) 81 (40–168)
Eligible arms 148 127
Number of arms
Two 51 (80%) 42 (78%)
Three 6 (9%) 5 (9%)
Four 7 (11%) 7 (13%)
Year of publication
1980–90 10 (16%) 4 (7%)
1991–2000 27 (42%) 23 (43%)
2001–12 27 (42%) 27 (50%)
Type of intervention
Medication only 38 (59%) 33 (61%)
Psychotherapy only 18 (28%) 15 (28%)
Both 8 (13%) 6 (11%)
Duration (weeks) 12 (10–12) 12 (10–12)
Continent
North America 30 (47%) 26 (48%)
Europe 19 (30%) 14 (26%)
Asia 6 (9%) 6 (11%)
Australia 3 (5%) 2 (4%)
South America 3 (5%) 3 (6%)
Multiple 3 (5%) 3 (6%)
Characteristics of included patients
Age (years) 36 (33–37) 36 (33–37)
Disease severity (YBOCS 
score) 
NA 25 (24–26)
Comorbid depression 27 (42%) 19 (35%)
Pharmaceutical industry sponsorship*
Yes 28/46 (61%) 25/39 (64%)
No 15/46 (33%) 12/39 (31%)
Unclear 3/46 (7%) 2/39 (5%)
Allowed patients on antidepressant medication†
Yes 13/18 (72%) 12/15 (80%)
No 4/18 (22%) 2/15 (13%)
Unclear 1/18 (6%) 1/15 (7%)
Data are n, median (IQR), n (%), or n/N (%). YBOCS=Yale-Brown Obsessive 
Compulsive Scale. NA=Not applicable. *For pharmacological trials. 
†For psychotherapeutic trials. 
Table 1: General characteristics of eligible studies 
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therapy study56 including 40 patients, 20 (50%) of whom 
had been randomly allocated to behavioural therapy. The 
behavioural therapy trial that used the waiting list as a 
control group56 was clearly an outlier in terms of eﬃ  cacy 
(mean YBOCS diﬀ erence from waiting list at the end of 
study –30·87). The network meta-analysis model gave an 
adequate ﬁ t to the data and we identiﬁ ed no evidence of 
inconsistency (posterior mean of the residual deviance was 
104·6 in the network meta-analysis assuming consistency 
and 105·8 assuming inconsistency compared with 107 data 
points). Further more, the deviance information criterion 
was similar for the models with (480·8) and without 
(479·1) the consistency assumption. The posterior median 
SD for the consistency model was 3·10 (95% credible 
interval 2·46–3·95), whereas for the inconsistency model, 
this value was reduced to 1·75 (1·18–2·53). 
Most active interventions showed a signiﬁ cant reduct-
ion in mean YBOCS compared with drug placebo, 
regardless of inclusion or exclusion of trials using waiting 
list controls (table 2). Venlafaxine and psycho logical 
placebo both showed reductions in mean YBOCS, but 
they were not signiﬁ cant. The waiting list was the only 
so-called intervention that was associated with an increase 
in mean YBOCS compared with drug placebo. The eﬀ ects 
of individual SSRIs were similar in magnitude. 
Clomipramine had a larger eﬀ ect compared with placebo 
than did SSRIs, but the diﬀ erence was not signiﬁ cant 
(table 3). All three psychotherapeutic interventions 
(behavioural therapy, cognitive therapy, and CBT) showed 
greater eﬃ  cacy than did drug placebo. However, in the 
full analysis, CBT was less eﬃ  cacious than were the other 
two and was not diﬀ erent from psychological placebo 
(appendix). Exclusion of studies that had used waiting list 
control groups led to a larger eﬀ ect for CBT, which was 
signiﬁ cantly diﬀ erent from psychological placebo and 
similar to the other two psychotherapies.
In the full network, both behavioural and cognitive 
therapy had a larger reduction in mean YBOCS than did 
SSRIs as a class (table 3). CBT also had a lower mean 
YBOCS than SSRIs as a class, but only after excluding 
waiting list controlled trials. We observed similar results 
when com paring diﬀ erent types of psychotherapies with 
clomi pramine as the reference (detailed results for all 
possible comparisons are shown in the appendix). How-
ever, in psychotherapeutic trials, most patients were 
taking stable doses of antidepressant medications for the 
whole duration of the trial. The same applies to the 
comparison between combinations of medications and 
psychotherapy versus psychotherapy alone as patients in 
these network comparisons were not in strict monotherapy 
(table 2, table 3). In all of these comparisons, diﬀ erences 
were small. Excluding waiting list controlled trials, the 
combination of behavioural therapy with clomipramine 
was associated with the largest eﬀ ect, but this com bination 
has been used in only a single trial.38
For all 64 trials included in the qualitative review, 
results of the risk of bias assessment for trials with at 
least one drug arm (46 [72%] of 64) and those with 
psychotherapy arms only (18 [28%] of 64) are presented 
in the appendix. Sequence generation (13 [20%] of 64) 
and random allocation concealment (eight [13%] of 64) 
were speciﬁ cally described (ie, low risk of bias) in few 
studies. In trials with psychotherapy arms, masking of 
participants or those delivering the intervention was not 
possible (seven [39%] of these 18 trials used outcome 
assessors who were masked to treatment allocation). In 
the drug only trials, speciﬁ cation of the double-blind 
method (eg, identical capsules) was described in 15 (39%) 
of 38 trials. Handling of in complete outcome data with 
an acceptable method was reported in 28 (61%) of the 
46 trials with at least one drug arm and six (33%) of the 
18 trials with psychotherapy arms only. A high proportion 
of the trials with drug arms were sponsored by 
pharmaceutical companies (table 1).
For the sensitivity analyses, we used the full network 
(detailed results given in the appendix). In the ﬁ rst 
analysis, we included the 33 (61%) trials with low overall 
(<25%) and diﬀ erential (<15%) attrition. This analysis led 
to a larger eﬀ ect for CBT than in the full analysis,which 
was then very similar to the other two psychotherapies. 
In the second analysis, we included 34 (63%) trials that 
met the criterion of low risk of bias in the domain of 
incomplete outcome assessment, and the main ﬁ nding 
was that clomipramine had a smaller eﬀ ect than in the 
full analysis that was not diﬀ erent from that of SSRIs. 
BT
BTCLO
CBT
CBTFLV
CIT
CLO
CT
ESCIT
FLV
FLX
HYP
PAR
PL PSYPL
SER
VEN
WL
Figure 2: Network diagram for effi  cacy analysis representing direct 
comparisons between individual  treatments
The size of each circle is proportional to the number of randomly allocated 
participants and the width of each line is proportional to the number of trials in 
each direct comparison. BT=behavioural therapy. CBT=cognitive behavioural 
therapy. CT=cognitive therapy. BTCLO=behavioural therapy and clomipramine. 
CBTFLV=cognitive behavioural therapy and fl uvoxamine. CIT=citalopram. 
CLO=clomipramine. ESCIT=escitalopram. FLV=fl uvoxamine. FLX=fl uoxetine. 
HYP=hypericum. PAR=paroxetine. PL=placebo. PSYPL=psychological placebo. 
SER=sertraline. VEN=venlafaxine. WL=waiting list.
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In this analysis, we excluded all cognitive therapy trials as 
they had reported completers analyses. In the third 
analysis, we included the 17 (31%) trials that used a 
masked outcome assessor. Overall, results were similar 
to those of the full analysis, but the power was 
compromised because of the small sample size. We 
carried out separate meta-regressions to test the eﬀ ect of 
length of trial, publication date, industry sponsorship, 
and inclusion of patients with current comorbid 
depression. The eﬀ ects of these variables were small, and 
none were signiﬁ cant (appendix).
Discussion
In this network meta-analysis, we found that several 
pharmacological and psychotherapeutic interventions 
can be considered more eﬃ  cacious than is drug placebo. 
We found that SSRIs are generally equally eﬃ  cacious, 
with no evidence to suggest that one drug is better than 
the others are. Their eﬀ ect compared with placebo is 
statistically signiﬁ cant, but the estimated mean diﬀ erence 
is generally moderate. In the full analysis, clomipramine 
showed a trend for a larger eﬀ ect than with SSRIs that 
was not statistically signiﬁ cant. This ﬁ nding contrasts 
with previous direct analyses, which postulated that 
clomipramine might be more eﬃ  cacious than are 
SSRIs.10 This comparison was sensitive to studies with 
incomplete outcome assessment: some old clomipramine 
trials reported completers analyses only, and exclusion of 
these trials led to a lower eﬀ ect for clomipramine than 
that of not excluding them, which was indistinguishable 
from that of SSRIs.
An unexpected ﬁ nding was that in our main analysis, 
CBT had a smaller eﬀ ect than that of behavioural or 
cognitive therapy. However, after exclusion of waiting 
list controlled trials, all diﬀ erences between psycho-
therapies were not signiﬁ cant. The waiting list was the 
only so-called intervention that led to an increase in 
mean YBOCS score compared with drug placebo, and 
psychological placebo was very similar to drug placebo 
after exclusion of waiting list controlled trials. Research 
has also shown that trials using control groups with no 
or minimal contact with therapists usually lead to grossly 
overestimated eﬀ ect sizes for active psycho therapeutic 
interventions.18,84,85 We obtained similar ﬁ ndings in the 
sensitivity analysis after exclusion of trials with high 
overall attrition to those from the main analysis after 
exclusion of waiting list controlled trials—ie, no 
diﬀ erence between psychotherapies. The evidence for 
cognitive therapy mostly comes from trials that had 
compared it with behavioural therapy, with most of them 
not reporting intention-to-treat analyses, and these trials 
might have overestimated the eﬀ ect of cognitive (and 
behavioural) therapy. The behavioural therapy trial that 
used the waiting list as a control group56 was clearly an 
outlier in terms of eﬃ  cacy, and excluding it from the 
analysis reduced the eﬀ ects for both behavioural and 
cognitive therapy, but not signiﬁ cantly. CBT has more 
links with other inter ventions and a more extensive 
network of trials than do cognitive and behavioural 
therapy and has been compared directly with several 
drugs in the same trial.26,71,74,75 Taking all of this evidence 
into account, our analysis does not support the view that 
the three types of psychotherapy have diﬀ erent eﬀ ects in 
obsessive-compulsive disorder.
Number 
of trials 
(n=54)*
Number of 
patients 
(n=6652)*
Mean YBOCS diff erence
Full network (n=54) Excluding waiting list 
controlled trials (n=48)
Drug placebo 23 1515 Reference Reference
Waiting list 6 97 5·62 (0·91 to 10·26) NA
Psychological placebo† 6 196 –4·15 (–8·65 to 0·49) –1·90 (–5·62 to 1·91)
SSRIs (class eff ect) 37 3158 –3·49 (–5·12 to –1·81) –3·62 (–4·89 to –2·34)
Fluoxetine 6 633 –3·46 (–5·27 to –1·58) –3·67 (–5·13 to –2·26)
Fluvoxamine 13 521 –3·60 (–5·29 to –1·95) –3·66 (–4·96 to –2·37)
Paroxetine 8 902 –3·42 (–5·10 to –1·61) –3·51 (–4·81 to –2·14)
Sertraline 7 565 –3·50 (–5·30 to –1·63) –3·68 (–5·14 to –2·30)
Citalopram 2 311 –3·49 (–5·62 to –1·31) –3·60 (–5·25 to –1·91)
Escitalopram 1 226 –3·48 (–5·61 to –1·23) –3·59 (–5·25 to –1·86)
Venlafaxine 2 98 –3·22 (–8·26 to 1·88) –3·21 (–7·01 to 0·69)
Clomipramine 13 831 –4·72 (–6·85 to –2·60) –4·66 (–6·26 to –3·05)
BT† 11 287 –14·48 (–18·61 to –10·23) –10·41 (–14·04 to –6·77)
CBT† 9 231 –5·37 (–9·10 to –1·63) –7·98 (–11·02 to –4·93)
Cognitive therapy† 6 172 –13·36 (–18·40 to –8·21) –9·45 (–13·76 to –5·19)
Hypericum 1 30 –0·15 (–7·46 to 7·12) –0·13 (–5·93 to 5·68)
CBT and fl uvoxamine 1 6 –7·50 (–13·89 to –1·17) –8·81 (–13·75 to –3·88)
BT and clomipramine 1 31 –12·97 (–19·18 to –6·74) –11·68 (–16·73 to –6·65)
Data in parentheses are 95% credible intervals. YBOCS=Yale-Brown Obsessive Compulsive Scale. BT=behavioural 
therapy. CBT=cognitive behavioural therapy. NA=not applicable. *Individual trials could be included in more than 
one treatment category. †Several patients randomly allocated into these psychotherapeutic interventions were 
allowed to take stable doses of antidepressants and remain on the same dose without further adjustments. 
Table 2: Treatment effi  cacy compared with drug placebo 
Mean YBOCS diff erence  
in full network (n=54)
Mean YBOCS 
diff erence excluding 
waiting list controlled 
trials (n=48)
SSRIs (class eff ect) Reference Reference
Clomipramine –1·23 (–3·41 to 0·94) –1·05 (–2·73 to 0·63)
BT* –10·99 (–15·14 to –6·75) –6·79 (–10·44 to –3·11)
CBT* –1·88 (–5·52 to 1·76) –4·36 (–7·34 to –1·40)
Cognitive therapy* –9·87 (–14·91 to –4·74) –5·83 (–10·17 to –1·51)
CBT and fl uvoxamine –4·03 (–10·36 to 2·21) –5·19 (–10·09 to –0·33)
BT and clomipramine –9·48 (–15·78 to –3·14) –8·01 (–13·18 to –2·95)
Data in parentheses are 95% credible intervals. YBOCS=Yale-Brown Obsessive 
Compulsive Scale. BT=behavioural therapy. CBT=cognitive behavioural therapy. 
*Several patients randomly allocated into these psychotherapeutic interventions 
were allowed to take stable doses of antidepressants and remain on the same 
dose without further adjustments.
Table 3: Effi  cacy of psychological and pharmacological interventions 
compared with SSRIs 
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Our analysis shows that all psychotherapies, either in the 
full dataset (for behavioural and cognitive therapy) or after 
exclusion of the waiting list controlled trials (for CBT), were 
more likely to lead to a larger eﬀ ect than were medications. 
Some previous meta-analyses have reported similar results 
in favour of psychotherapy. For example, Cuijpers and 
colleagues86 examined the diﬀ erential eﬀ ect of 
pharmacotherapy and psychotherapy in major depression, 
dysthymia, panic disorder, social anxiety disorder, and 
obsessive-compulsive disorder, and reported a positive 
eﬀ ect for psychotherapy compared with medications only 
for obsessive-compulsive disorder. One important 
limitation exists that, to our knowledge, has not been 
recognised before: most patients included in trials that 
used exclusively psychotherapeutic inter ventions were 
allowed to continue taking their anti depressant 
medications. Combination trials that had both psycho-
therapeutic and drug arms, or arms with both 
psychotherapy and drugs, explicitly excluded patients on 
antidepressant medications by design (and half of these 
trials were of CBT and half were of behavioural therapy). 
Therefore, psychotherapy trials have essentially compared 
diﬀ erent psycho thera peutic interventions in patients taking 
stable doses of anti depressant medications. Some evidence 
exists from other trials that focused exclusively on treat-
ment-refractory patients that addition of CBT for patients 
with SSRI-refractory obsessive-compulsive disorder is 
more eﬃ  cacious than is either psychological placebo87 or 
risperidone.88 In our analysis, although patients were 
symptomatic at study recruitment, what the eﬀ ect would be 
if patients had been tapered oﬀ  their anti depressant 
medication before randomi sation is unknown because 
such studies have not been done. This issue has also been 
reported in meta-analyses of bipolar depression in which 
randomly allocated patients are allowed to continue using 
their mood stabilisers or anxiolytic medications.89 In any 
case, generalisation of these results for psychotherapeutic 
inter ventions in patients not taking concurrent 
anti depressant medications is diﬃ  cult. There fore, the 
question of what is better as monotherapy in obsessive-
compulsive disorder—medications or psychotherapy—
cannot be answered given the current evidence.
Our analysis has several limitations. Most studies were 
of short-term duration. As most of the studies that tested 
the eﬃ  cacy of psychotherapeutic interventions included 
patients who were taking stable doses of antidepressant 
medications, generalisation of these results to patients 
not on medications is not possible. We were unable to 
test diﬀ erent doses of the same drug to investigate 
potential dose-response associations.90 Because of the 
scarce data, we could not treat alternative dosing schemes 
in pharmacological trials as diﬀ erent nodes in the 
network. Several old studies only reported completers 
analyses, including all cognitive therapy studies, limiting 
the usefulness of the sensitivity analysis in this domain. 
We did not consider the relative eﬃ  cacy of the various 
interventions in diﬀ erent symptom dimensions of 
obsessive-compulsive disorder, and generalisation of the 
results in subgroups of patients with speciﬁ c symptoms, 
such as hoarding, should be made with caution.
The results of our analysis generally support current 
National Institute for Health and Care Excellence 
guidelines.7 For pharmacological management, the 
recommendation to use SSRIs rather than clomipramine 
as the ﬁ rst-line agents is supported by our ﬁ ndings since 
SSRIs have better tolerability than does clomipramine 
and we identiﬁ ed no convincing evidence for clomi-
pramine being more eﬃ  cacious than are SSRIs. For 
non-pharmacological management, all three types of 
psychotherapy are probably more eﬃ  cacious than is 
non-speciﬁ c therapy, but evidence is limited to patients 
taking stable doses of antidepressant medication before 
initiating psychotherapy. The combined initiation of both 
medication and psychotherapy (either behavioural ther-
apy or CBT) seemed an eﬃ  cacious treatment. In our 
analysis excluding waiting list controlled trials, this 
combined treatment was best, but with considerable 
uncertainty. Given that most psychotherapeutic trials can 
also be considered variants of combination trials (since 
most patients were taking stable doses of antidepressant 
medications), the combination of SSRIs or clomipramine 
with psychotherapy is likely to oﬀ er more beneﬁ t to 
patients with severe illness than is mono therapy, but 
more research is needed than at present to support this 
hypothesis, including cost-eﬀ ectiveness analyses.
Further research should try to diﬀ erentiate more clearly 
than at present the eﬀ ect of medications versus psycho-
therapy and monotherapy versus combined therapy. Trials 
that investigate the eﬀ ect of psychotherapy should monitor 
use of antidepressants in included patients or recruit 
patients who are willing to taper oﬀ  their antidepressant 
medication before entering randomisation. As obsessive-
compulsive dis order is a very heterogeneous condition, 
more pragmatic trials of longer duration than have been 
done so far are needed to test the eﬃ  cacy of existing 
interventions in patients encountered in daily clinical 
practice (including those with other comorbid conditions) 
and the augmenting eﬀ ect of medications in addition to 
psychotherapy or vice versa in patients with treatment-
refractory obsessive-compulsive disorder.
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